The WHO European Office for the Prevention and Control of Noncommunicable Diseases organized an expert meeting on monitoring of digital marketing of unhealthy products to children and adolescents in June 2018. Based on that meeting, this report aims to provide a tool to support Member States in moni...toring digital marketing of unhealthy products to children; the resulting tool – the so-called CLICK monitoring framework – is flexible and can be adapted to national context. The report also describes current digital marketing strategies, the challenges arising from current practices, and some policy options to tackle digital marketing to children and adolescents.
more
This paper provides case studies of several food product improvement policies from across the WHO European Region. The aim is to share country experience, assess the various merits of the different approaches, discuss lessons learned, and provide guidance for best practice that may be more widely ap...plicable across the European Region.
more
Every day, fake medicines and medical products are sold at street corners, in open air markets or on unregulated websites in several countries in the African Region. These poor quality, unsafe medicines and pharmaceutical products promote drug resistance and lead to loss of confidence in health prof...essionals, manufacturers and distributors and in health systems. In an effort to protect people’s health, the WHO Regional Director for Africa, Dr Matshidiso Moeti, has proposed a strategy aimed at strengthening National Medicine Regulatory Authorities (NMRAs) in order to ensure that only safe, good quality and effective medical products are available.
more
A workshop of “first mover” countries to exchange experience and identify wider policy implications for the WHO European Region
The World Health Organization (WHO) European Region continues to be severely affected by diet-related noncommunicable diseases (NCDs), obesity and, in some countries, ...micronutrient deficiencies.
In order to drive further progress on improving dietary intake and food product improvement, the WHO Regional Office for Europe, Public Health England and the Royal Institute of International Affairs (Chatham House) co-convened a workshop of “first mover” countries in March 2019.
more
Public Report
PQMC 0001-001-04 WHO PQMC Public Report November/2016, version 8.0
This report, published in conjunction with a summary overview of results of rounds 1–8, is the eighth and final report in a series of laboratory-based evaluations of rapid diagnostic tests (RDTs) for malaria. It provides a comparative measure of their performance in a standardized way to distingui...sh between well and poorly performing tests.
These results constitute the laboratory evaluation component of the WHO prequalification process for malaria RDTs and inform the current WHO procurement recommendations. In round 8, 35 RDTs from 17 manufacturers were assessed. For the first time the evaluation included an assessment of product performance against a panel of P. falciparum parasites with pfhrp2/3 gene deletions and therefore not expressing HRP2.
more
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
Public Report
PQMC 0003-003-00 WHO PQMC PR June/2015, version 2.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
Rwanda Guidelines for variation to registered pharmaceutical products.
The aim of this protocol is to support the conduct of entomological comparative efficacy assessments for vector control products and the associated non-inferiority analysis. This evidence is used to inform discussions within the guidelines development context as to whether a new vector control prod...uct should be considered as covered by one or more existing WHO recommendations or not. Alternatively, the evidence may inform the extension of an existing WHO recommendation or the development of a new one, provided that non-inferiority is demonstrated
more
This guideline is intended to provide requirements to applicants wishing to submit
applications for registration of medicines in Botswana.